Real ChatGPT answer · index seedKTXuhHhrXakcompleteHealth and wellness · women's healthinformational
Are there any newly approved non-hormonal pharmaceutical treatments specifically indicated for severe vasomotor symptoms that can be safely prescribed alongside current HRT regimens?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
Are there any newly approved non-hormonal pharmaceutical treatments specifically indicated for severe vasomotor symptoms that can be safely prescribed alongside current HRT regimens?
3 real searches · 1 real-search pass
FDA approval elinzanetant Lynkuet October 2025 label concomitant hormone therapy vasomotor symptomsGoogle ↗
OBSERVED
FDA fezolinetant Veozah prescribing information concomitant hormone therapy safety not studiedGoogle ↗
OBSERVED
NAMS nonhormone therapy vasomotor symptoms elinzanetant HRT concomitant use guidance 2025Google ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
FDA approval elinzanetant Lynkuet October 2025 label concomitant hormone therapy vasomotor symptoms Google ↗
FDA fezolinetant Veozah prescribing information concomitant hormone therapy safety not studied Google ↗
NAMS nonhormone therapy vasomotor symptoms elinzanetant HRT concomitant use guidance 2025 Google ↗
- Drug Trials Snapshots: LYNKUET · fda.gov
- These highlights do not include all the information needed to use LYNKUET safely and effectively. See full prescribing information for LYNKUET. LYNKUET® (elinzanetant) capsules, for oral use Initial U.S. Approval: 2025 · dailymed.nlm.nih.gov
- Lynkuet-PI · labeling.bayerhealthcare.com
- DailyMed · dailymed-beta.nlm.nih.gov
- label · accessdata.fda.gov
- VA/DOD CLINICAL PRACTICE GUIDELINE FOR MENOPAUSE · healthquality.va.gov
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
FDA approval elinzanetant Lynkuet October 2025 label concomitant hormone therapy vasomotor symptoms OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
FDA fezolinetant Veozah prescribing information concomitant hormone therapy safety not studied OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
NAMS nonhormone therapy vasomotor symptoms elinzanetant HRT concomitant use guidance 2025 OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |